Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Safety of GSK2838232 Tablet Formulation
NCT03234036Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of GSK2838232 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by GSK. Primary endpoints: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinite Time at 120 hours, Maximum Observed Concentration at 120 hours and 14 more. Started Aug 2017; status: completed.
02
Drugs
GSK2838232
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03234036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03234036.